Compare Corning Incorporated (GLW) vs Summit Therapeutics Inc (SMMT) Price & Performance

Corning (GLW) trades at $167.02, up 5.88% over 24 hours, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS up 30% year-over-year. Revenue growth is accelerating, driven by optical communications and AI data center demand, though valuation multiples remain elevated. Recent news highlights analyst upgrades citing improved fundamentals post-sell-off.

Outlook is positive with a consensus price target of $193.33 (15.8% upside), supported by AI infrastructure growth and profitability improvements. Risks include high valuation sensitivity, competitive pressures, and execution challenges in scaling solar and automotive segments. Institutional sentiment is bullish with 56.75% buy ratings, but technical indicators warn of near-term overbought conditions.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.